This study will evaluate the safety of subcutaneous (SC) epoetin beta (NeoRecormon) in adults with solid tumors being treated with platinum-based chemotherapy capable of inducing anemia. The anticipated time on study treatment is 16 weeks, and the target sample size is approximately 208 individuals.

Inclusion Criteria:

• Adults at least 18 years of age
• Presence of solid tumor(s)
• Receiving platinum-based therapy capable of inducing anemia

Exclusion Criteria:

• Red blood cell transfusion within 7 days prior to study drug
• Relevant acute or chronic bleeding requiring therapy within 3 months prior to study drug
• Women who are pregnant or breastfeeding